Trials / Conditions / Refractory B-cell Acute Lymphoblastic Leukemia
Refractory B-cell Acute Lymphoblastic Leukemia
6 registered clinical trials studyying Refractory B-cell Acute Lymphoblastic Leukemia — 1 currently recruiting.
| Status | Trial | Sponsor | Phase |
|---|---|---|---|
| Recruiting | CAR-T-19 Injection in the Treatment of CD19-positive Relapsed/Refractory B-ALL NCT06179524 | Beijing Yongtai Ruike Biotechnology Company Ltd | Phase 2 |
| Withdrawn | A Phase I Study of Mosunetuzumab for Relapsed or Refractory B-Cell Acute Lymphoblastic Leukemia NCT05961696 | M.D. Anderson Cancer Center | Phase 1 |
| Unknown | A Clinical Study Evaluating the Safety and Efficacy of BinD19 Treatment in R/R ALL and Lymphoma Subjects NCT03156101 | Shenzhen BinDeBio Ltd. | Phase 1 / Phase 2 |
| Completed | Study of UCART19 in Pediatric Patients With Relapsed/Refractory B Acute Lymphoblastic Leukemia NCT02808442 | Institut de Recherches Internationales Servier | Phase 1 |
| Withdrawn | Study of Efficacy and Safety of CTL019 in Adult ALL Patients NCT02167360 | Abramson Cancer Center at Penn Medicine | Phase 2 |
| Completed | Study of Efficacy and Safety of CTL019 in Pediatric ALL Patients NCT02228096 | Novartis Pharmaceuticals | Phase 2 |